| Routes of administration | Topical[1] |
|---|---|
| Class | Minoxidil sulfotransferase stimulant |
| Synonyms | AB103 |
AB-103 is a minoxidil sulfotransferase stimulant which is under development for the treatment of alopecia (hair loss) as an adjunct to the hair loss drug minoxidil.[1] It is used topically.[1] The drug works by stimulating the enzyme SULT1A1 in hair follicles which converts minoxidil into its active form minoxidil sulfate and which has been found to predict minoxidil's clinical effectiveness.[1][2][3][4] It was originated by Applied Biology and is under development by Safety Shot.[1] As of February 2024, AB-103 is in phase 3 clinical trials for treatment of alopecia.[1] It has been in this stage of development since at least April 2019, but there have been no more recent updates on its development since then.[1] The chemical structure of AB-103 does not yet appear to have been disclosed.[1]
See also
References
- ^ "AB 103". AdisInsight. 27 February 2024. Retrieved 23 October 2025.
- ^ Goren A, Naccarato T (September 2018). "Minoxidil in the treatment of androgenetic alopecia". Dermatologic Therapy. 31 (5). doi:10.1111/dth.12686. PMID 30155952
- ^ Roberts J, Desai N, McCoy J, Goren A (2014). "Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia". Dermatologic Therapy. 27 (4): 252–254. doi:10.1111/dth.12130. PMID 24773771
- ^ Goren A, Shapiro J, Roberts J, McCoy J, Desai N, Zarrab Z, Pietrzak A, Lotti T (2015). "Clinical utility and validity of minoxidil response testing in androgenetic alopecia". Dermatologic Therapy. 28 (1): 13–16. doi:10.1111/dth.12164. PMID 25112173